Bristol Myers, with Breyanzi nod in hand, eyes faster cell therapy production

Producing cell therapies isn’t easy—and that’s a fact Bristol Myers Squibb knows only too well. FDA hang-ups at a viral vector plant delayed CAR-T therapy Breyanzi, sinking a Celgene deal-related payout worth some $6.4 billion.